Snapshot from Aug 29, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Capricor class action over FDA SAP changes
Regulatory securities class action

Capricor class action over FDA SAP changes

Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Aug 29, 2026

Sentiment
-60
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA's negative assessment of Capricor's clinical data and the subsequent securities class action have severely damaged investor confidence, leading to a 64% stock price drop. The lawsuit and regulatory scrutiny could further depress Capricor's market valuation and hinder its ability to obtain approval for Deramiocel.

Biotechnology Pharmaceuticals
Event Summary

Kahn Swick & Foti, LLC (KSF) announced a class action securities lawsuit against Paragon Therapeutics, Inc. on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit, filed in the United States — United States District Court for the Southern District of California, alleges that Capricor and certain executives failed to disclose material information, violating federal securities laws. The claims stem from the FDA's July 27, 2026 publication of briefing documents ahead of an advisory committee meeting to review the Biologics License Application for Deramiocel, Capricor's lead product candidate. The FDA found that Capricor made changes to the pre-specified statistical analysis plan (SAP) without prior FDA review or agreement, and considered the post-study analyses post-hoc and exploratory. The FDA also noted an unfavorable benefit-risk profile for Deramiocel due to lack of evidence of effectiveness. Following this news, Capricor's stock fell 64% to close at $7.00 per share on July 27, 2026. Investors have until September 28, 2026 to request lead plaintiff appointment.

Key Actions
100 Kahn Swick & Foti filed class action lawsuit Paragon Therapeutics
100 United States — Food and Drug Administration released briefing documents Paragon Therapeutics
100 Paragon Therapeutics stock dropped
Entities Involved
priv
Paragon Therapeutics
Capricor is the defendant in the class action and the subject of FDA criticism. Its stock plummeted 64% following the FDA briefing documents, and it faces legal liabilities and potential regulatory setbacks for Deramiocel.
Importance 100.0 Sentiment -90.0
govactor
United States — Food and Drug Administration
The FDA's critical briefing documents triggered the stock drop and the lawsuit. The agency's regulatory actions are central to the event, though its own sentiment is neutral as it performs its oversight role.
Importance 80.0 Sentiment -20.0
priv
Kahn Swick & Foti
KSF is the law firm leading the class action, seeking recoveries for investors. The firm benefits from high-profile securities litigation, potentially enhancing its reputation and revenue.
Importance 70.0 Sentiment 20.0
govactor
United States — United States District Court for the Southern District of California
The court is where the class action is pending. Its rulings will determine the outcome of the litigation, affecting Capricor and investors.
Importance 40.0 Sentiment 0.0
per
Lewis Kahn
Lewis Kahn, Managing Partner at KSF, is the primary contact for investors and is actively involved in the class action, representing the firm's interests.
Importance 30.0 Sentiment 10.0
per
Charles Foti
Charles Foti, a partner at KSF and former Louisiana Attorney General, is involved in the case, lending his name and experience to the litigation.
Importance 30.0 Sentiment 10.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
Paragon Therapeutics related ↔ United States — United States District Court for the Southern District of California
United States — Food and Drug Administration related ↔ Kahn Swick & Foti
United States — Food and Drug Administration related ↔ United States — United States District Court for the Southern District of California
United States — Food and Drug Administration related ↔ Lewis Kahn
Kahn Swick & Foti related ↔ United States — United States District Court for the Southern District of California
Kahn Swick & Foti related ↔ Lewis Kahn
Kahn Swick & Foti related ↔ Charles Foti
United States — United States District Court for the Southern District of California related ↔ Lewis Kahn
United States — United States District Court for the Southern District of California related ↔ Charles Foti
Lewis Kahn managing partner ↔ Charles Foti Lewis Kahn is the Managing Partner and a founding partner of Kahn Swick & Foti, LLC, a law firm where Charles Foti is a
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.